Ovarian cancer | Guidance and guideline topic | NICE

5 new

and

0 updated

products since January 2017.

NICE Pathways - mapping our guidance

Technology appraisal guidance

Bevacizumab for treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal) (TA353) August 2015
Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer (TA285) May 2013
Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer (TA284) May 2013
Guidance on the use of paclitaxel in the treatment of ovarian cancer (TA55) January 2003
Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy (TA381) January 2016
Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer (TA389) April 2016

Quality standards

Ovarian cancer (QS18) May 2012
Suspected cancer (QS124) June 2016

NICE Evidence summaries

Ovarian cancer (advanced): bevacizumab 7.5 mg/kg in combination with paclitaxel and carboplatin for first-line treatment (ESUOM21) October 2013

NICE Guidelines

Ovarian cancer: recognition and initial management (CG122) April 2011
Suspected cancer: recognition and referral (NG12) June 2015

Interventional procedures guidance

Ultra-radical (extensive) surgery for advanced ovarian cancer (IPG470) November 2013

In development

Niraparib for ovarian cancer [ID1041] (GID-TA10135) May 2018 Technology appraisal guidance
Ovarian (epithelial), fallopian and peritoneal cancer - pazopanib (maintenance) [ID545] (GID-TAG444) TBC Technology appraisal guidance
Ovarian cancer - vintafolide (with pegylated liposomal doxorubicin) [ID564] (GID-TAG332) TBC Technology appraisal guidance
Ovarian, fallopian tube and peritoneal cancer - rucaparib [ID1184] (GID-TA10168) May 2018 Technology appraisal guidance
Tests in secondary care to identify people at high risk of ovarian cancer (GID-DG10012) November 2017 Diagnostics guidance